Hoboken, NJ, December 28, 2015- Primary Immune Deficiency (PID) Patients and Investigators Needed for Clinical Phase III Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability and Safety of Subcutaneous Human Immunoglobulin (Octanorm 16.5%) in Patients with Primary Immunodeficiency Diseases.

You may be eligible for this study if:

- You are a patient age of 2 to 75 years
- have a confirmed diagnosis of PI and requiring immunoglobulin replacement therapy due to hypogammaglobulinaemia or agammaglobulinaemia.
- have been receiving at least 6 infusions on regular treatment with any IVIG with a minimum of the last 2 months on the same product prior to entering the study.
- do not have known history of adverse reactions to IgA in other products
- are not pregnant or nursing or plan to become pregnant during the course of the study
- BMI must be 40 or below
- Do not have severe liver function impairment
- No presence of renal function impairment
- No history of malignancies of lymphoid cells and immunodeficiency with lymphoma

If your physician is not participating in this study, he or she may be able to refer you to a participating physician and you would continue your infusions/injections at your local physician’s office or at home.

If you would like more information regarding this study, please contact: michael.eppolito@octapharma.com or audrey.wadsworth@octapharma.com. You may also visit www.clintrials.gov for additional study information.

If you are a physician wishing to participate or obtain additional information regarding this study, please contact: michael.eppolito@octapharma.com or audrey.wadsworth@octapharma.com.